The FDA has approved a prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

Viridian Therapeutics, Inc.’s VRDN share price has surged by 5.71%, which has investors questioning if this is right time to ...

As of Tuesday, April 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 7.59%, which has investors questioning if ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Vyvgart Hytrulo is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase. It is indicated for the treatment of adult patients with generalized ...

The data convincingly show that the transcription factor Sp1 regulates ephrin-mediated axon guidance in the spinal cord. Although the authors show that Sp1 and its co-activators p300 and CBP are ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...